MEI Pharma reports $38.3M cash; continues evaluating strategic alternatives

Lite Strategy, Inc.

Cash, cash equivalents, and short-term investments at June 30, 2024: $38.3 million, with no outstanding debt.
Board commenced evaluation of strategic alternatives on July 22, 2024; Oppenheimer & Co. retained as exclusive financial adviser.
Reduction-in-force commenced August 1, 2024, continuing in stages; clinical development of voruciclib discontinued.
Options include out-licensing programs and M&A; company will not disclose developments unless completed or required.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.